Table 2. Summary of Patient Characteristics, Calendar Year, and Regimens at HAART Initiation.
| FH-Argentina | HUCFF-Brazil | FA-Chile | GHESKIO-Haiti | IHSS/HE-Honduras | INNSZ-Mexico | IMTAvH-Peru | Combined | |
| n = 720 (14%) | n = 522 (10%) | n = 546 (11%) | n = 1646 (33%) | n = 324 (6%) | n = 414 (8%) | n = 854 (17%) | n = 5026 | |
| Female | 209 (29%) | 175 (33.5%) | 69 (12.6%) | 879 (53.4%) | 128 (39.5%) | 52 (12.6%) | 253 (29.6%) | 1765 (35.1%) |
| Age a | 36 (31, 43) | 37 (32, 45) | 36 (30, 42) | 39 (33, 45) | 37 (31, 41) | 35 (29, 42) | 34 (28, 40) | 37 (31, 44) |
| Route of Infection | ||||||||
| Heterosexual b | 249 (47.3%) | 219 (62.2%) | 160 (29.6%) | - | 323 (99.7%) c | 148 (35.7%) | 583 (68.8%) | 1682 (56%) c |
| IVDU | 66 (12.5%) | 7 (2%) | 2 (0.4%) | - | 1 (0.3%) | 0 (0%) | 0 (0%) | 76 (2.5%) |
| MSM | 208 (39.5%) | 106 (30.1%) | 378 (70%) | - | 0 (0%) | 263 (63.5%) | 264 (31.1%) | 1219 (40.6%) |
| Other | 3 (0.6%) | 20 (5.7%) | 0 (0%) | - | 0 (0%) | 3 (0.7%) | 1 (0.1%) | 27 (0.9%) |
| Missing | 194 (26.9%) | 170 (32.6%) | 6 (1.1%) | 1646 (100%) | 0 (0%) | 0 (0%) | 6 (0.7%) | 2022 (40.2%) |
| Clinical Stage | ||||||||
| not AIDS b | 487 (68%) | 95 (26.2%) | 302 (55.4%) | 944 (57.4%) | 186 (59.2%) | 226 (56.2%) | 305 (37.3%) | 2545 (53%) |
| AIDS | 229 (32%) | 267 (73.8%) d | 243 (44.6%) | 702 (42.6%) | 128 (40.8%) | 176 (43.8%) | 512 (62.7%) | 2257 (47%) |
| Missing | 4 (0.4%) | 160 (25.4%) | 1 (0.1%) | 0 (0%) | 10 (2.3%) | 12 (2.1%) | 37 (2.8%) | 224 (4.7%) |
| CD4 (cells/mL) a | 155 (52, 245) | 153 (53, 240) | 116 (32, 193) | 102 (37, 192) | 105 (55, 185) | 88 (33, 193) | 79 (32, 164) | 105 (38, 200) |
| <50 b | 150 (24.2%) | 80 (24.1%) | 142 (32.3%) | 434 (30.4%) | 49 (19.1%) | 136 (34.3%) | 254 (36.9%) | 1245 (29.9%) |
| 50-99 | 85 (13.7%) | 51 (15.4%) | 65 (14.8%) | 258 (18.1%) | 75 (29.3%) | 74 (18.7%) | 145 (21.1%) | 753 (18.1%) |
| 100-199 | 163 (26.2%) | 78 (23.5%) | 133 (30.3%) | 407 (28.5%) | 77 (30.1%) | 95 (24%) | 165 (24%) | 1118 (26.9%) |
| 200-349 | 156 (25.1%) | 102 (30.7%) | 91 (20.7%) | 283 (19.8%) | 47 (18.4%) | 84 (21.2%) | 99 (14.4%) | 862 (20.7%) |
| ≥350 | 67 (10.8%) | 21 (6.3%) | 8 (1.8%) | 47 (3.3%) | 8 (3.1%) | 7 (1.8%) | 25 (3.6%) | 183 (4.4%) |
| Missing e | 99 (13.8%) | 190 (36.4%) | 107 (19.6%) | 217 (13.2%) | 68 (21%) | 18 (4.3%) | 166 (19.4%) | 865 (17.2%) |
| CD4<200 or AIDS | ||||||||
| No b | 255 (35.5%) | 116 (25.1%) | 96 (17.6%) | 360 (21.9%) | 72 (22.8%) | 74 (17.9%) | 127 (15.1%) | 1100 (22.2%) |
| Yes | 463 (64.5%) | 347 (74.9%) | 449 (82.4%) | 1286 (78.1%) | 244 (77.2%) | 339 (82.1%) | 716 (84.9%) | 3844 (77.8%) |
| Missing | 2 (0.3%) | 59 (11.3%) | 1 (0.2%) | 0 (0%) | 8 (2.5%) | 1 (0.2%) | 11 (1.3%) | 82 (1.6%) |
| HIV-1 RNA (log10) a | 5 (4.5, 5.4) | 4.7 (3.6, 5.2) | 5.1 (4.7, 5.5) | - | 5 (4.7, 5) | 4.9 (4.9, 4.9) | 5.2 (4.7, 5.5) | 5 (4.6, 5.4) |
| <10,000 b | 13 (2.6%) | 8 (5.3%) | 1 (0.3%) | - | 2 (2.2%) | 0 (0%) | 33 (6.8%) | 57 (2.9%) |
| 10,000-99,999 | 20 (4%) | 23 (15.2%) | 1 (0.3%) | - | 4 (4.3%) | 3 (0.8%) | 0 (0%) | 51 (2.6%) |
| ≥100,000 | 470 (93.4%) | 120 (79.5%) | 383 (99.5%) | - | 87 (93.5%) | 353 (99.2%) | 451 (93.2%) | 1864 (94.5%) |
| Missing | 217 (30.1%) | 371 (71.1%) | 161 (29.5%) | 1646 (100%) | 231 (71.3%) | 58 (14%) | 370 (43.3%) | 3054 (60.8%) |
| Weight (kg) a | 66 (60, 74) | 65 (58, 74) | 64 (56, 72) | 53 (47, 60) | 59 (51, 65) | 61 (53, 71) | 57 (50, 64) | 56 (49, 64) |
| Missing | 647 (89.9%) | 399 (76.4%) | 325 (59.5%) | 92 (5.6%) | 94 (29%) | 105 (25.4%) | 212 (24.8%) | 1874 (37.3%) |
| Hemoglobin (g/dL) a | 13.8 (11.8, 14.6) | 11.7 (10, 13.7) | 12.3 (10.7, 13.7) | 10 (9, 11) | 12.3 (10.8, 13.5) | 14.2 (11.8, 15.7) | 11.3 (10.3, 12.7) | 11 (9.9, 13) |
| Missing | 697 (96.8%) | 267 (51.1%) | 343 (62.8%) | 528 (32.1%) | 143 (44.1%) | 165 (39.9%) | 683 (80%) | 2826 (56.2%) |
| Calendar Year | ||||||||
| 1996-1999 | 6 (0.8%) | 136 (26.1%) | 0 (0%) | 0 (0%) | 3 (0.9%) | 0 (0%) | 5 (0.6%) | 150 (3%) |
| 2000-2001 | 42 (5.8%) | 124 (23.8%) | 35 (6.4%) | 0 (0%) | 5 (1.5%) | 3 (0.7%) | 11 (1.3%) | 220 (4.4%) |
| 2002-2003 | 210 (29.2%) | 118 (22.6%) | 290 (53.1%) | 699 (42.5%) | 104 (32.1%) | 147 (35.5%) | 50 (5.9%) | 1618 (32.2%) |
| 2004-2005 | 325 (45.1%) | 80 (15.3%) | 221 (40.5%) | 923 (56.1%) | 100 (30.9%) | 161 (38.9%) | 520 (60.9%) | 2330 (46.4%) |
| 2006-2007 | 137 (19%) | 64 (12.3%) | 0 (0%) | 24 (1.5%) | 112 (34.6%) | 103 (24.9%) | 268 (31.4%) | 708 (14.1%) |
| Initial Regimen | ||||||||
| NNRTI | 469 (65.1%) | 288 (55.2%) | 510 (93.4%) | 1569 (95.3%) | 311 (96%) | 287 (69.3%) | 788 (92.3%) | 4222 (84%) |
| EFV-based | 316 (67.4%) | 238 (82.6%) | 326 (63.9%) | 922 (58.8%) | 220 (70.7%) | 271 (94.4%) | 176 (22.3%) | 2469 (58.5%) |
| NVP-based | 153 (32.6%) | 50 (17.4%) | 184 (36.1%) | 647 (41.2%) | 91 (29.3%) | 16 (5.6%) | 612 (77.7%) | 1753 (41.5%) |
| PI | 21 (2.9%) | 167 (32%) | 23 (4.2%) | 15 (0.9%) | 10 (3.1%) | 16 (3.9%) | 21 (2.5%) | 273 (5.4%) |
| Boosted PI | 188 (26.1%) | 43 (8.2%) | 4 (0.7%) | 7 (0.4%) | 2 (0.6%) | 106 (25.6%) | 36 (4.2%) | 386 (7.7%) |
| Other | 42 (5.8%) | 24 (4.6%) | 9 (1.6%) | 55 (3.3%) | 1 (0.3%) | 5 (1.2%) | 9 (1.1%) | 145 (2.9%) |
| ZDV Containing | 542 (75.3%) | 422 (80.8%) | 432 (79.1%) | 1515 (92%) | 229 (70.7%) | 289 (69.8%) | 631 (73.9%) | 4060 (80.8%) |
| Most Common Regimens | ||||||||
| 3TC,ZDV,EFV | 249 (34.6%) | 196 (37.5%) | 237 (43.4%) | 855 (51.9%) | 218 (67.3%) | 194 (46.9%) | 121 (14.2%) | 2070 (41.2%) |
| 3TC,ZDV,NVP | 130 (18.1%) | 37 (7.1%) | 167 (30.6%) | 593 (36%) | 1 (0.3%) | 9 (2.2%) | 475 (55.6%) | 1412 (28.1%) |
| 3TC,D4T,NVP | 19 (2.6%) | 6 (1.1%) | 6 (1.1%) | 49 (3%) | 90 (27.8%) | 2 (0.5%) | 95 (11.1%) | 267 (5.3%) |
| 3TC,D4T,EFV | 51 (7.1%) | 29 (5.6%) | 55 (10.1%) | 55 (3.3%) | 0 (0%) | 21 (5.1%) | 23 (2.7%) | 234 (4.7%) |
| 3TC,ABC,ZDV | 32 (4.4%) | 22 (4.2%) | 8 (1.5%) | 55 (3.3%) | 0 (0%) | 4 (1%) | 2 (0.2%) | 123 (2.4%) |
a
Continuous variables are reported as medians (interquartile range).
b
Percentages are computed using the number of patients with a non-missing value.
c
IHSS/HE-Honduras did not differentiate between heterosexual and MSM routes of infection. All are listed here as heterosexual.
d
HUCFF-Brazil classified most patients with CD4<200 as having clinical AIDS.
e
Sites may have high percentages of missing CD4, HIV-1 RNA, weight, and hemoglobin values because data were not collected within the specified time frames to count as baseline measurements (see Methods: Data Sources and Measurements).